CH₃CH₃

NMDA Glycine-site Agents

The NMDA glutamate receptor only opens when a second molecule, glycine or D-serine, is bound to a separate site on it. That co-agonist site is a way to turn NMDA signalling up or down more gently than ketamine-style channel blockers do, and drug developers have tried both directions. HA-966 is a 1960s compound whose two mirror-image forms do different things. Rapastinel is a small peptide that went through clinical trials for depression without being approved. Neboglamine was developed as a modulator of the site. Sarcosine is a natural amino acid that raises glycine levels by blocking its reuptake, and was tested as an add-on treatment in schizophrenia.

None of these is an approved medicine in the United States, and none is sold as one. What they share is a target, not an effect: a result for one does not transfer to the others, and the research versions sold online carry no assurance of identity or purity beyond the seller's.

No posts here yet.

Tell us something